TCS, HDFCBANK, SBI Liquid Fund (G)
Bafna Pharmaceuticals Ltd.
Bafna Pharma
NSE
₹ 0.00
0.00 (0.00)%
Healthcare
Small-cap
With a market cap of ₹18.90L Cr.
Moderate Volatility
Stock is 1.13x as volatile as index
| EX-Date | Purpose |
|---|---|
| 25 06 2021 | Audited Results |
| 05 08 2021 | Quarterly Results |
| 16 09 2021 | Inter alia, to consider the proposal of availing working capital / term loan facility for expansion program and any other business with the permission of the Chair |
| 12 11 2021 | Rights Issue & Quarterly Results Inter alia also consider the following business: 1. To consider and approve the proposal for various avenues for raising funds, including and in particular Rights Issue to meet capital requirements of the Company. |
| 10 02 2022 | Quarterly Results |
| 21 03 2022 | Inter alia, to consider resignation and appointment of Company Secretary (KMP) of the Company and any other business with the permission of chair. |
| 26 05 2022 | Audited Results |
| 11 08 2022 | Quarterly Results |
| 11 11 2022 | Quarterly Results |
| 08 02 2023 | Quarterly Results |
| 07 04 2023 | Inter alia, to consider and approve the appointment of Company Secretary cum Compliance Officer and any other business with the permission of the Chair |
| 24 05 2023 | Audited Results |
| 27 05 2023 | Audited Results (Revised) |
| 26 06 2023 | Inter alia, to consider and approve the appointment of : 1. Mr. Vinayak Dinesh Dendukuri (DIN: 07601309) as Additional Director designated as Whole-time Director ? Operation. 2. Mr. Upendar Mekala Reddy (DIN: 08898174) as Additional Director designated as Non-Executive Non-independent Director; 3. Mr. Krishna Yeachuri (DIN: 00066898) as Additional Director designated as Non-Executive Independent Director, and any other business with the permission of the Chair. |
| 11 08 2023 | Quarterly Results |
| 09 11 2023 | Quarterly Results |
| 12 02 2024 | Quarterly Results |
| 11 11 2024 | Quarterly Results |
| 06 02 2025 | Quarterly Results |
News
No News data available
